Sunshine Biopharma, Inc.

NasdaqCM:SBFM Rapport sur les actions

Capitalisation boursière : US$5.7m

Sunshine Biopharma Résultats passés

Passé contrôle des critères 0/6

Sunshine Biopharma's earnings have been declining at an average annual rate of -33.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 85.4% per year.

Informations clés

-33.6%

Taux de croissance des bénéfices

94.4%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.0%
Taux de croissance des recettes85.4%
Rendement des fonds propres-15.7%
Marge nette-12.1%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12
Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sunshine Biopharma acquires Nora Pharma for C$30M

Oct 20

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Sunshine Biopharma reports 1H results

Aug 04

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Apr 17

Ventilation des recettes et des dépenses

Comment Sunshine Biopharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqCM:SBFM Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2430-4122
31 Mar 2427-4112
31 Dec 2324-5112
30 Sep 2320-27141
30 Jun 2315-28131
31 Mar 239-27121
31 Dec 224-2791
30 Sep 220-331
30 Jun 220-521
31 Mar 220-721
31 Dec 210-1221
30 Sep 210-1421
30 Jun 210-1120
31 Mar 210-920
31 Dec 200-310
30 Sep 200-210
30 Jun 200-210
31 Mar 200-110
31 Dec 190-110
30 Sep 190-100
30 Jun 190-210
31 Mar 190-210
31 Dec 180-210
30 Sep 180-210
30 Jun 180-110
31 Mar 180-110
31 Dec 170-110
30 Sep 170-210
30 Jun 170-310
31 Mar 170-310
31 Dec 160-310
30 Sep 160-310
30 Jun 160-210
31 Mar 160-200
31 Dec 150-200
30 Sep 150-110
30 Jun 150-110
31 Mar 150-210
31 Dec 140-210
30 Sep 140-210
30 Jun 140-210
31 Mar 140-210

Des revenus de qualité: SBFM is currently unprofitable.

Augmentation de la marge bénéficiaire: SBFM is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: SBFM is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.

Accélération de la croissance: Unable to compare SBFM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: SBFM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement des fonds propres

ROE élevé: SBFM has a negative Return on Equity (-15.66%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé